Date: 2013-09-10
Type of information: R&D agreement
Compound:
Company: AstraZeneca (UK) Hadasit (Israel)
Therapeutic area: Cancer - Oncology - Respiratory diseases - Metabolic diseases
Type agreement: R&D
Action mechanism:
Disease: cancer, respiratory diseases, diabetes
Details: * On September 10, 2013, AstraZeneca and Hadasit, the commercial arm and technology transfer company of Hadassah University Hospitals (Hadassah), jave announced an alliance to identify, evaluate and jointly develop novel medicines across a broad range of diseases to address unmet patient needs, with a primary focus on cancer, respiratory diseases and diabetes. The agreement provides a framework that brings together complementary skills to harness and foster medical innovation: Hadasit will provide innovations, technologies and research capabilities originating from Hadassah facilities and teams in Israel; AstraZeneca will bring its proven track record in global research and drug discovery.
Under the terms of the agreement, Hadasit and Hadassah scientists will work in collaboration with teams from AstraZeneca’s Innovative Medicines & Early Development organization for an initial period of three years. Research projects included in the collaboration will primarily address cancer, respiratory diseases and diabetes. These are key components of the three core therapy areas announced by AstraZeneca as part of its strategy to drive growth and achieve scientific leadership: Oncology; Cardiovascular & Metabolic Disease; and Respiratory, Inflammation & Autoimmunity. The agreement spans both biologics and ‘small molecule’ compounds. Financial details were not disclosed.
Financial terms:
Latest news:
